New RA drug candidate enters first human tests
Disease control
Completed
This early-stage study tested a new drug called KD6005 in 73 people. First, healthy volunteers received a single dose to check safety. Then, people with rheumatoid arthritis received multiple doses. The main goal was to see if the drug is safe and how the body processes it.
Phase: PHASE1 • Sponsor: Shanghai Kanda Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 04:15 UTC